- Home
- CVKD vs GDTC Comparison
CVKD vs GDTC Comparison
Compare CVKD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- GDTC
- Stock Information
- Founded
- CVKD 2022
- GDTC 2018
- Country
- CVKD United States
- GDTC Singapore
- Employees
- CVKD N/A
- GDTC N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- GDTC Health Care
- Exchange
- CVKD Nasdaq
- GDTC Nasdaq
- Market Cap
- CVKD 29.5M
- GDTC 21.5M
- IPO Year
- CVKD 2023
- GDTC 2023
- Fundamental
- Price
- CVKD $10.54
- GDTC $1.89
- Analyst Decision
- CVKD Strong Buy
- GDTC Buy
- Analyst Count
- CVKD 1
- GDTC 1
- Target Price
- CVKD $32.00
- GDTC $5.00
- AVG Volume (30 Days)
- CVKD 27.7K
- GDTC 18.1K
- Earning Date
- CVKD 08-11-2025
- GDTC 01-01-0001
- Dividend Yield
- CVKD N/A
- GDTC N/A
- EPS Growth
- CVKD N/A
- GDTC N/A
- EPS
- CVKD N/A
- GDTC N/A
- Revenue
- CVKD N/A
- GDTC $368,838.00
- Revenue This Year
- CVKD N/A
- GDTC $5.37
- Revenue Next Year
- CVKD N/A
- GDTC N/A
- P/E Ratio
- CVKD N/A
- GDTC N/A
- Revenue Growth
- CVKD N/A
- GDTC N/A
- 52 Week Low
- CVKD $5.70
- GDTC $1.20
- 52 Week High
- CVKD $22.90
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CVKD 37.37
- GDTC 37.08
- Support Level
- CVKD $11.25
- GDTC $1.85
- Resistance Level
- CVKD $11.88
- GDTC $1.95
- Average True Range (ATR)
- CVKD 0.77
- GDTC 0.10
- MACD
- CVKD -0.03
- GDTC -0.02
- Stochastic Oscillator
- CVKD 2.95
- GDTC 28.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.